Assessment of Evidence Quality in Inflammatory Bowel Disease Guidance: The Use and Misuse of GRADE by Gordon, Morris & Guyatt, Gordon
Assessment of evidence quality in IBD guidance: The use and misuse of GRADE 
 
Short Title: Evidence quality in IBD guidance 
Authors: Professor Morris Gordon1,2, Professor Gordon Guyatt3 
1. School of Medicine, University of Central Lancashire, UK 
2. Families Division, Blackpool victoria Hospital, UK 
3. Department of Clinical Epidemiology and Biostatistics, McMaster University, Canada 
No grant support  
Abbreviations: 
AGA – American Gastroenterological Association 
ACG – American College of Gastroenterology  
CD – Crohn’s Disease 
ESPGHAN – European society for Pediatric Gastroenterology, Hepatology and Nutrition 
ECCO – European Crohn’s and Colitis Organisation 
GRADE – Grading of Recommendations Assessment, Development and Evaluation 
IBD – Inflammatory Bowel Disease 
NICE – National institute for Health and Care Excellence 









Professor Morris Gordon 
Room HA340,  
Harrington building 
University of Central Lancashire,  
Preston,  
Lancashire, PR1 2HE, UK 
Email: mgordon@uclan.ac.uk   
Phone: ++44 1772 895945 
 
Disclosures: none relevant to declare.  
Professor Gordon has previously received none restricted travel grants to attend internal 
scientific meetings from various companies, but received no other funding or performed any 
other roles for them. Since July 2019, Professor Gordon has made a personal undertaking to 
receive no future pharma funding for any activity, to comply with the enhanced 
requirements of Cochrane COI policies. Both Professor Gordon and Professor Guyatt work in 
the academic fields of synthesis and gain personal academic advantages from publication of 
such works. 
Author Contributions: 
Professor Gordon conceived this paper, led the writing and has approved the final version. 








A core principle of evidence based medicine is that optimal clinical care must be grounded in 
systematic summaries of the best available evidence.  Over 40 years, the methodology of systematic 
reviews has evolved sophisticated approaches to framing study questions, conducting 
comprehensive searches, evaluating risk of bias, and most recently and perhaps most crucially 
making judgements of the quality (also referred to as confidence or certainty) of the evidence.  More 
recently – largely in the last 20 years – methodologists have developed and applied scientific 
standards to the process of moving from evidence to recommendations; that is, the process of 
creating clinical practice guidelines. 
In this article, we will discuss this evolution in the particular context of inflammatory bowel disease.  
Although clinical leaders and stakeholder organisations within gastroenterology have embraced 
scientific standards for systematic reviews and guidelines, problematic practices that risk 
undermining the evidence based credentials of guidelines and undoing the progress made over the 
last decades still remain. 
Evidence based medicine in Gastroenterology 
The term ‘Evidence Based Medicine’ that first appeared in the literature in 19911, refers to a 
paradigm shift in approach to health professionals’ use of evidence to guide their clinical practice, an 
approach grounded in systematic reviews of the best available evidence. Calls have been issued in 
this very journal for the field of gastroenterology to keep up with the trend as ‘current systematic 
review articles seem to be published outside the field’2. It wasn’t until 2002 that the first systematic 
review was published in the journal3, although in 2018 there were 12 such articles, emphasising the 
core role they now play in the wider scholarly discourse. 
Rigorous systematic reviews involve a number of steps, including formulating explicit eligibility 
criteria, postulating possible subgroup effects, conducting a comprehensive search, judging the risk 
of bias of individual eligible studies, and presenting coherent evidence summaries.  As with all 
important methodologies within scholarly endeavours, execution at this stage can be capricious, 
with recent work suggesting that systematic reviews completed outside the Cochrane collaboration 
looking at identical contexts and questions will differ by up to 65% in the evidence they include4. If, 
however, these vital and generally well agreed steps are performed transparently, meticulously and 
without bias, this will set the appropriate stage for the next even more challenging step, which is 
deciding on the quality of the resulting body of evidence. 
At the time systematic reviews captured the evidence summary science, multiple systems of judging 
quality of evidence existed, none of the remotely rigorous or satisfactory.  Methodologists were 
aware of considerations such as inconsistency in research results, concerns about publication bias 
(suppression of negative trial results), and whether the magnitude of intervention benefits and 
harms is large enough to be important to patients.  They did not, however, have an approach that 
would optimally integrate such issues.  
GRADE contributing to Evidence Based Medicine and guidelines 
The informal organization that became the GRADE working group began to meet in 20005 published 
its first guidance in the BMJ in 2004, and has continued to publish further detailed guidance 
(including a six-part series in the BMJ in 2008, and a thus far 22 part series in the Journal of Clinical 
Epidemiology).  There are now more than 110 organisations from 19 countries that have endorsed 
or use this approach to judging the quality of evidence bearing on clinical questions, and developing 
corresponding clinical practice guidelines, including key organisations within gastroenterology. There 
is no scholarly discourse that highlights any clear competing approach or identifies fundamental 
flaws in this approach that is now seen as the universal gold standard to assess quality of evidence 
and strength of recommendations.  
A recently published example by one of the authors of this commentary highlights the GRADE 
approach to quality of evidence in systematic reviews and how it supports, but in no way mandates, 
specific recommendations for practice.  In an updated Cochrane review on the use of 5-ASA agents 
for maintenance of post-surgical remission in Crohn’s disease6, the authors identified a statistically 
significant reduction in relapses when using 5-ASA agents compared with placebo. During a follow-
up period of 12 to 72 months, 36% (131/361) of 5-ASA participants relapsed compared to 43% 
(160/369) of placebo participants (RR 0.83, 95% CI 0.72 to 0.96).  
When considering a GRADE approach to rating the quality of the evidence specific to relapse 
prevention, as this was analysis of randomised controlled trials, the quality of the evidence begins as 
high in GRADE’s four category rating (high, moderate, low, and very low quality evidence).  Five 
categories of limitations can, however, results in rating down evidence quality.  Risks of bias (item 1) 
for the trials in this comparison were low across key items; there was no evidence of publication bias 
(item 2); the populations and outcomes were appropriate suggesting no concerns of indirectness 
(item 3); and inconsistency (item 4) was low, no evidence of statistical heterogeneity. Thus, none of 
these four elements required rating down of quality. There were, however, relatively low numbers 
of events (291) and the smallest plausible effect (the upper boundary of the confidence interval, a 
4% relative risk reduction), might not be important to patients.  The authors therefore rated down 
the quality of the evidence by one level for imprecision, leaving us moderately confident of an 
important impact of 5-ASA in reducing recurrence following post-surgical remission in patients with 
Crohn’s disease  
This relatively robust evidence will be considered in a variety of international guidelines in the 
future.  Despite the quality or certainty of the evidence from the review, guideline committees will 
not necessarily issue a strong clinical recommendation for 5-ASA.  Following GRADE methodology, 
guideline developers will need to consider harms and burdens associated with the intervention, 
costs, feasibility, acceptability and equity – as well as alternative treatment options and the 
magnitude of effect. This last element may be particularly relevant, as the absolute risk reduction in 
recurrences over a period of 1-5 years is 7%, meaning that clinicians must treat 14 patients to 
prevent one clinical relapse over this time period6. This may lead those in a guideline process to 
consider that despite the moderate certainty of the evidence, the relative small magnitude of effect 
(weak recommendation).  
This is the ultimate achievement of GRADE for clinicians and patients, with quality of evidence not 
necessarily implying strong recommendations or vice versa, but a requirement to nonetheless assess 
evidence in an objective manner in all cases. This balanced approach to considering not just the 
quality but wider context of evidence is at the heart of evidence based medicine and one that is now 
well reflected across growing guidance in IBD.  
 
Current IBD guidance and quality of evidence according to GRADE 
Evidence based treatment guidelines for IBD have become the increasing standard in the last 
decade. It is not surprising that whilst these began to be released around the time the GRADE 
process was being endorsed by key stakeholders, early guideline committees lacking familiarity in 
this approach did not use the tool. Instead, these used an approach to consider evidence quality 
which mostly focussed on individual study level assessments, but no method to consider the 
evidence base as a whole when making recommendations. 
Table 1 presents the most recent publications on IBD from the major guideline producing societies 
across USA and Europe. It can be seen that whilst a number of these recent guidelines have fully 
embraced the GRADE process, there are some clear areas of divergence. One reason for this is 
understandable in that a society may be updating their processes to use GRADE. An example of this 
was the recently published ECCO adult Crohn’s disease medical management guidelines7, which is 
the first from the society to use GRADE.  
A more alarming situation is the attribution of use of GRADE within a guideline process, when what 
authors are using is a misinterpreted or misappropriated version of GRADE or indeed committees 
simply not using GRADE at all.  Three examples (UK National Institute for health and care excellence 
NICE CD guideline update8, ESPGHAN UC9 guidelines and ECCO surgical CD guidelines10) illustrate the 
problem.  
The UK NICE guidelines8 have a standard operating procedure aligned with GRADE11. Whilst there is 
no question within these procedures or their underpinning GRADE guidelines that authors rate the 
quality of an entire body of evidence for a given outcome, the authors present GRADE analysis of 
individual studies.  This is truly a non sequitar: two GRADE domains, inconsistency and publication 
bias apply only to bodies of evidence; for two others, risk of bias and directness, individual studies 
can differ and GRADE provides guidance for making across study ratings; and for precision the 
evaluation is made on pooled estimates rather than individual studies.  Both these guidelines link to 
external methodologies (NICE guideline policies11 and Cochrane Handbook12) that accurately 
summarize GRADE guidance, yet neither follow the summaries presented there.  
In the case of the recent ESPGHAN guidelines for Paediatric UC9, it is unclear. There is mention of 
GRADING evidence, but whilst readers may infer alignment within this rhetoric, the methods involve 
scoring of individual studies much more aligned with earlier systems. Finally, the recent ECCO 
surgical CD guidelines10 explicitly address and choose to not use GRADE. They state that ‘due to the 
peculiarities of the surgical literature, appraisal of the systematically researched literature was 
conducted according to the Oxford methodology.’ We believe this is again a non-sequitur. Whilst a 
given body of evidence may be relatively weaker than other areas in a field, using an out of date and 
out of consensus method for judging evidence does not solve this issue. This is akin to using a 
fractured lens to examine broken glass. It merely leaves readers even more unclear as to the nature 
of the evidence. As the example above showed, higher certainty evidence does not necessitate 
strong recommendations any more than lower quality evidence limits committees making stronger 
recommendations. Therefore, using a lower fidelity tool to reflect lower quality evidence offers no 
advantages to the guideline committee and further complicates the role of guideline developers and 
readers. 
These fundamental mischaracterizations or misuses represent a serious matter.  The purpose of 
GRADE quality of evidence ratings is to allow systematic reviewers to present to summarize the 
hugely complex issue of quality of evidence in a single rating for each outcome that the review has 
addressed and in turn present this evidence to guideline committees to use in a clear and 
transparent fashion.  What evidence users need, and are entitled to, is quality ratings that apply to 
the entire body of evidence.  
The overall impact of such inconsistent approaches are to substitute a careful systematic approach 
that includes assessment of inconsistency and indirectness and systematic consideration of between 
study differences with a former approach sometimes referred to as GOBSAT (good old boys sitting 
around a table).  GOBSAT substitutes intuition for careful, systematic guidance-informed 
assessment, opening the process to judgments that flow from raters’ conflicts of interest.  When 
claiming use of GRADE, guidelines undermine the progress in understanding, using the status of the 
system that has almost universal acceptance internationally while potentially misleading 
unsuspecting clinicians. Similarly, when substituting or diverging from GRADE without true 
justification, clinicians may not necessarily be able to interpret the relative impact on the overall 
process or utility of the resulting guideline. 
We are not suggesting deliberate motives to mislead – though authors may, consciously or 
subconsciously, giving more free play to their particular opinions in such approaches.   Rather, this is 
complex area and such aberrations are understandable; irrespective of the motivation, the adverse 
impact is a serious matter. The examples given are recently published guidelines relevant to dozens 
of countries with a catchment of millions of IBD patients. It is vital that the responsible organizations 
rectify their practices in future guidelines. 
Future directions in IBD and gastroenterology guidelines 
There is a growing integration of GRADE approaches to IBD and wider Gastroenterology guidance. 
Many of the recent publications were the first time these societies have integrated GRADE 
approaches and we would strongly advise they follow the institute of medicine’s guidance and 
employ a GRADE methodologist, preferably as co-chair, participating in the guideline (as indeed 
some organizations have adopted as standard practice)14, as well as following the guidance from the 
GRADE working group on applying or using GRADE17. 
This movement towards homogenous approaches of evidence collection, evaluation, and 
presentation may offer new opportunities for collaboration that remain unexploited. In key areas, 
numerous groups associated – and not associated – with specialty societies are simultaneously 
conducting comprehensive searches (including for unpublished studies), undertaking risk of bias 
ratings, extracting data, contacting authors, and conducting GRADE quality of evidence assessments. 
A collaborative approach to these activities, with the various guideline developers using this single 
shared data set to inform their own technical reviews and guidelines would be far more efficient 
manner that the current duplication.  Such collaboration will ensure the most rigorous reviews, 
consistency of evidence, and enhanced expert methodological support through sharing of limited 
resources.  
We strongly encourage key opinion leaders and senior professionals within these societies to discuss 
the possibility of this sort of collaboration, but this must be built on an alignment to GRADE as 
standard. 
Table 1. Current Use of GRADE in guidelines for IBD 
Guideline title (reference) Society and 
Location 




Association (AGA) Institute 
Guideline on Management of 
Mild-to-Moderate Ulcerative 
Colitis13 
AGA, USA 2019 CDG author reports YES 
Guideline states ‘Although the quality of evidence was a key factor in determining the 
strength of the recommendations (Table 3), the panel also considered the balance 
between benefit and harm of interventions, patients’ values and preferences, and 
resource utilization.’  
Judgement of methodology presented 
GRADE methodology was used to prepare the background information for the guideline 
and the accompanying technical review and evidence profile. Citation of society 
publication describing application of GRADE to quality assessment of evidence. 
Evidence summaries with quality and strength of recommendation ratings are 
presented and consistent with GRADE14 
 
ACG Clinical Guideline: 






2018 CDG author reports YES 
To evaluate the level of evidence and strength of recommendations, we used the 
Grading of Recommendations Assessment, Development, and Evaluation (GRADE) 
system.  
 
Judgement of methodology presented 
Statements are presented with both the quality of evidence rating and strength of 
recommendation, in line with GRADE, however underpinning evidence profiles are not 
presented. 
Guidelines on 
the management of 
inflammatory bowel disease in 
adults16 
British Society of 
Gastroenterology, 
UK 
2019 CDG author reports YES 
GRADE of evidence for each statement ‘considered study type, risk of bias, 
inconsistency, Indirectness, imprecision, publication bias, effect size, plausible 
confounding variables, and dose response gradient if applicable. The strength of 
recommendation was assessed based on considerations of desirable and undesirable 
anticipated effects, the certainty of the evidence of effects, any important uncertainty 
about or variability in how much people value the outcome, whether the balance of 
these effects favours the intervention or comparison, the acceptability of intervention 
to key stakeholders, and feasibility of intervention implementation.’ 
Judgement of methodology presented 
Significant details of methodology, however, despite some appendices being 
mentioned, evidence profiles are not presented. Detailed discussion of efficacy and 
safety data in main text. 
Crohn's disease: management 
Evidence review for post-
surgical maintenance of 
remission8 
National Institute 
for Health and Care 
Excellence, UK 
2019 CDG author reports NO 
The guideline cites a source methodology document, stating that: ‘The quality is then 
summarised by individual study and, if using the GRADE approach, by outcome’11 
Judgement of methodology presented 
In this evidence review, GRADE was used to assess individual studies. Authors note that 
due to this, inconsistency cannot be ranked and so this is not considered across the 
evidence base. Imprecision rating considered only on Confidence intervals, no 
consideration of event numbers or other elements. Publication bias not considered. 
Risk of bias of individual studies, not outcome level. Evidence profiles are presented, 
but as stated are not compliant with GRADE. 
ECCO Guidelines on 






2020 CDG author reports YES 
Based on the GRADE workflow and selection of committee members considered 
knowledge of the GRADE methodology. All panellists received adequate training in 
GRADE before starting the process. 
Judgement of methodology presented 
Online appendices with detailed information of the GRADE process and judgements 
and GRADE evidence profiles. 
ECCO Guidelines on 






2020 CDG author reports NO 
‘These Guidelines abide by the GRADE methodology in terms of framing clinically 
relevant questions to draw evidence-based statements and recommendations. 
However, due to the peculiarities of the surgical literature, appraisal of the 
systematically researched literature was conducted according to the Oxford 
methodology (grading from evidence level [EL] 1: systematic review of randomised 
controlled trials to EL 5: expert opinion).’ 
 
Judgement of methodology presented 
No use of GRADE in synthesis or evidence profiling. No clear justification for not using 
GRADE, except the suggestion the evidence base was poor 
Management of Paediatric 
Ulcerative Colitis, Part 1: 
Ambulatory Care—An Evidence-








of Crohn’s and 
Colitis, Europe 
 CDG author reports NO 
‘grading of evidence according to the Newcastle-Ottawa assessment scales for case-
control and cohort studies (19) and according to the Cochrane Handbook for clinical 
trials (20) (Supplemental Table 2: tables of evidence with grading’ 
Judgement of methodology presented 
No overall outcome or statement level GRADE ranking of evidence given. Whilst 
GRADING is stated, this does not appear to be an explicit statement on the use of 
GRADE, as individual study level judgements are made in the evidence profiles. 
Additionally, these judgements are not consistent not consistent with Cochrane 
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